Real‐World Selection of Venetoclax‐Obinutuzumab Versus <scp>BTK</scp> Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Time-limited and continuous targeted therapies are used with similar frequency for CLL/SLL, with selection shaped by age, TP53 aberrations, geography, and patient preferences. These findings highlight the importance of personalized care and the need to reduce access barriers to time-limited strategies.
Authors
- Mona Shafey (ORCID: https://orcid.org/0000-0002-2423-6865)
- Robert Tidswell
- Anthea Peters (ORCID: https://orcid.org/0000-0002-2570-339X)
- Carolyn Owen (ORCID: https://orcid.org/0000-0003-4110-1708)
- Robert Puckrin (ORCID: https://orcid.org/0000-0002-8918-6598)
- Russell Sterrett (ORCID: https://orcid.org/0000-0001-9273-7234)
- Sarah Perry (ORCID: https://orcid.org/0000-0002-3583-1600)
- Nanette Cox‐Kennett
Institutions
- University of Alberta (CA)
- University of Calgary (CA)
- Occupational Cancer Research Centre (CA)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1111/ejh.70137
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00